Kuba S, Soutome S, Hagiwara Y, Kikawa Y, Iwamoto T, Sangai T, Harao M, Yamaguchi T, Taji T, Igarashi A, Kajimoto Y, Sakurai N, Yamanouchi K, Watanabe K, Maeda N, Suzuki M, Maeda S, Toh U, Ebata A, Iwakuma N, Matsunuma R, Yamaguchi M, Mukai H; CSPOR-BC.,
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer Jpn J Clin Oncol

Shoji A, Kudo K, Murashita K, Nakaji S, Igarashi A.,
Reduction in all-cause medical and caregiving costs through innovative health awareness projects in a rural area in Japan: a retrospective cohort study BMC Health Serv Res

Esaki M, Igarashi A, Tsukamoto S, Sugawara S, Sekiguchi M, Fujinaga A.,
[Health Economic Evaluation of Surgical Treatment for Cancer] Gan To Kagaku Ryoho

Takayama Y, Tsukamoto S, Kudose Y, Takamizawa Y, Moritani K, Esaki M, Kanemitsu Y, Igarashi A.,
Cost-effectiveness of surveillance intervals after curative resection of colorectal cancer Jpn J Clin Oncol

Yoshihara H, Fukuda M, Hanawa T, Tsugawa Y.,
Identifying sex from pharyngeal images using deep learning algorithm Sci Rep

Harigai M, Fujii T, Sakai R, Igarashi A, Shoji A, Yamaguchi H, Iwasaki K, Makishima M, Yoshida A, Okada N, Yamashita K, Kawahito Y.,
Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database Mod Rheumatol

Kohli M, Maschio M, Lee A, Igarashi A.,
Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine Vaccine

Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Masuda S, Osawa R, Hosokawa N, Nakashima K, Kamura H, Imura H, Inoue H, Matsuzaka S, Sugimoto Y, Kuwamitsu O, Motohashi I, Morikawa T, Oda R, Hoshina Y, Matono T, Teshigahara O, Sando E, Asami S, Kudo S, Akizuki N, Muto Y, Hayakawa T, Kishaba T, Ohara Y, Kubo Y, Suzuki M, Morimoto K.,
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) Expert Rev Vaccines

Fust K, Joshi K, Beck E, Maschio M, Kohli M, Lee A, Hagiwara Y, Van de Velde N, Igarashi A.,
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan Vaccines (Basel)

Kato M, Ono T, Deguchi H, Ohmagari N, Igarashi A.,
Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan Vaccine X

LoPresti M, Igarashi A, Sonohara Y, Bowditch S.,
A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan Epilepsy Behav

Tanaka S, Igarashi A, De Moor R, Li N, Hirozane M, Hong LW, Wu DB, Yu DY, Hashim M, Hutton B, Tantakoun K, Olsen C, Mirzayeh Fashami F, Samjoo IA, Cameron C.,
A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices Value Health

LoPresti M, Igarashi A, Sonohara Y, Bowditch S.,
The emotional burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy: A qualitative study in Japan Epilepsy Behav

Erskine J, Abrishami P, Bernhard JC, Charter R, Culbertson R, Hiatt JC, Igarashi A, Purcell Jackson G, Lien M, Maddern G, Soon Yau Ng J, Patel A, Rha KH, Sooriakumaran P, Tackett S, Turchetti G, Chalkidou A.,
An international consensus panel on the potential value of Digital Surgery BMJ Open

Maruyama-Sakurai K, Tachimori H, Saito E, Kohsaka S, Segawa Y, Miyata H, Igarashi A.,
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan Diabetes Obes Metab

Yoshihara H, Tonoike T, Ohno H, Nishiuchi S, Igarashi A.,
Impact of Initial Treatment Policies on Long-term Complications and Costs in Japanese Patients with Type 2 Diabetes: A Real-World Database Study Diabetes Ther

Kurai D, Mizukami A, Preckler V, Verelst F, Molnar D, Matsuki T, Ho Y, Igarashi A.,
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis Expert Rev Vaccines

Nakatani E, Ohno H, Satoh T, Funaki D, Ueki C, Matsunaga T, Nagahama T, Tonoike T, Yui H, Miyakoshi A, Tanaka Y, Igarashi A, Kumamaru H, Kuriyama N, Sugawara A.,
Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients PLoS One

Igarashi A, Onishi H, Shioyama Y, Matsumoto Y, Takayama K, Matsuo Y, Yamashita H, Miyakawa A, Matsushita H, Aoki M, Nihei K, Kimura T, Koba R, Lee DW, Ito K.,
Cost-Utility Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients With Stage I Non-small Cell Lung Cancer in Japan Int J Radiat Oncol Biol Phys

Sasayama K, Nishimura E, Yamaji N, Ota E, Tachimori H, Igarashi A, Arata N, Yoneoka D, Saito E.,
Current Use and Discrepancies in the Adoption of Health-Related Internet of Things and Apps Among Working Women in Japan: Large-Scale, Internet-Based, Cross-Sectional Survey JMIR Public Health Surveill

Nagasawa K, Ohata M, Igarashi A, Arashiro T, Ogawa T, Ohkusu M, Takeuchi N, Shizuno K, Kurihara E, Yoshida M, Kodama T, Abe K, Hoshino T, Arii J, Takeshita K, Hishiki H, Ota S, Takahashi Y, Omata Y, Nakazawa T, Someya T, Ishiwada N.,
Prospective hospital-based cohort studies of Respiratory Syncytial Virus (RSV) infections in infants under one year during and after the SARS-CoV-2 pandemic in Japan Int J Infect Dis

Sato K, Niimi Y, Ihara R, Iwata A, Suzuki K, Nemoto K, Arai T, Higashi S, Igarashi A, Kasuga K, Awata S, Iwatsubo T.,
Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer's Disease in Japan Alzheimers Res Ther

Sasayama K, Nishimura E, Yamaji N, Ota E, Tachimori H, Igarashi A, Arata N, Yoneoka D, Saito E.,
Correction: Current Use and Discrepancies in the Adoption of Health-Related Internet of Things and Apps Among Working Women in Japan: Large-Scale, Internet-Based, Cross-Sectional Survey JMIR Public Health Surveill

Hamada T, Oyama H, Igarashi A, Kawaguchi Y, Lee M, Matsui H, Michihata N, Nakai Y, Fushimi K, Yasunaga H, Fujishiro M.,
Optimal age to discontinue long-term surveillance of intraductal papillary mucinous neoplasms: comparative cost-effectiveness of surveillance by age Gut

Saeki S, Iwatani T, Kitano A, Sakurai N, Tanabe Y, Yamauchi C, Igarashi A, Kajimoto Y, Kuba S, Hara F, Sagara Y, Ohno S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.,
Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives Breast Cancer

Izumi C, Matsuyama R, Asaoka M, Iwasaki K, Takeshima T, Murphy S, Teng L, Igarashi A.,
Valvular heart disease in Japan: Characteristics and treatment of patients in acute care hospitals in 2019 J Cardiol

Izumi C, Matsuyama R, Yamabe K, Iwasaki K, Takeshima T, Murphy SME, Teng L, Igarashi A.,
In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data Clinicoecon Outcomes Res

Ishii M, Kawai T, Tsujita K, Igarashi A, Suzuki M, Deguchi H, Fernandez J.,
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan Circ J

Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Ito T, Ikeda H, Kamura H, Motohashi I, Kimura Y, Komino M, Arai H, Kuwamitsu O, Akuzawa N, Sando E, Morikawa T, Imura H, Inoue H, Hayakawa T, Teshigahara O, Ohara Y, Suzuki M, Morimoto K.,
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) Expert Rev Vaccines

Naito Y, Mishima S, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E.,
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors Int J Clin Oncol

Kato M, Yoneyama-Hirozane M, Iwasaki K, Matsubayashi M, Igarashi A.,
Health-related quality of life in health states corresponding to different stages of perianal fistula associated with Crohn's disease: a quantitative evaluation of patients and non-patients in Japan J Mark Access Health Policy

Asakawa K, Idehara K, Saito A, Mitomi T, Igarashi A.,
[Cost-Effectiveness Analysis and Budget Impact Analysis of Enzalutamide for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer] Hinyokika Kiyo

Igarashi A.,
[Life and Money? Life or Money? -Health Economic Assessment and Value Assessment for Oncology Medications] Gan To Kagaku Ryoho

Suda K, Sakai M, Obama K, Yoda Y, Shibasaki S, Tanaka T, Nakauchi M, Hisamori S, Nishigori T, Igarashi A, Noshiro H, Terashima M, Uyama I.,
Three-year outcomes of robotic gastrectomy versus laparoscopic gastrectomy for the treatment of clinical stage I/II gastric cancer: a multi-institutional retrospective comparative study Surg Endosc

Kuwana M, Tamura N, Yasuda S, Fujio K, Shoji A, Yamaguchi H, Iwasaki K, Makishima M, Kawata Y, Yamashita K, Igarashi A.,
Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data Mod Rheumatol

Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E.,
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors Int J Clin Oncol

Kajimoto Y, Honda K, Suzuki S, Mori M, Tsubouchi H, Nakao K, Azuma A, Shibutani T, Nagao S, Koyanagi T, Kohara I, Tamaki S, Yabuki M, Teng L, Fujiwara K, Igarashi A.,
Association between financial toxicity and health-related quality of life of patients with gynecologic cancer Int J Clin Oncol

Morita I, Kurazono K, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Ha C, Igarashi A.,
Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis J Med Econ

Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E.,
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition Int J Clin Oncol

Igarashi A, Sakata Y, Azuma-Kasai M, Kamiyama H, Kawaguchi M, Tomita K, Ishii M, Ikeda M.,
Linguistic and Psychometric Validation of the Cognition Bolt-On Version of the Japanese EQ-5D-5L for the Elderly J Alzheimers Dis

Saito Y, Igarashi A, Nakayama T, Fukuma S.,
Prevalence of multimorbidity and its associations with hospitalisation or death in Japan 2014-2019: a retrospective cohort study using nationwide medical claims data in the middle-aged generation BMJ Open

Sekiguchi M, Igarashi A, Toyoshima N, Takamaru H, Yamada M, Esaki M, Kobayashi N, Saito Y.,
Cost-effectiveness analysis of computer-aided detection systems for colonoscopy in Japan Dig Endosc

Takami A, Kato M, Deguchi H, Igarashi A.,
Value elements and methods of value-based pricing for drugs in Japan: a systematic review Expert Rev Pharmacoecon Outcomes Res

Ezura M, Sawada K, Takushima Y, Igarashi A, Teng L.,
A systematic review of the characteristics of data assessment tools to measure medical doctors' work-related quality of life J Mark Access Health Policy

Saeki S, Iwatani T, Kitano A, Sakurai N, Tanabe Y, Yamauchi C, Igarashi A, Kajimoto Y, Kuba S, Hara F, Sagara Y, Ohno S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.,
Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives Breast Cancer

Igarashi A, Azuma MK, Zhang Q, Ye W, Sardesai A, Folse H, Chavan A, Tomita K, Tahami Monfared AA.,
Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation Neurol Ther

Yang Z, Purba FD, Shafie AA, Igarashi A, Wong EL, Lam H, Van Minh H, Lin HW, Ahn J, Pattanaphesaj J, Jo MW, Mai VQ, Busschbach J, Luo N, Jiang J.,
Do health preferences differ among Asian populations? A comparison of EQ-5D-5L discrete choice experiments data from 11 Asian studies Qual Life Res

Hashimoto Y, Hayashi A, Tonegawa T, Teng L, Igarashi A.,
Cost-saving prediction model of transfer to palliative care for terminal cancer patients in a Japanese general hospital J Mark Access Health Policy

Yagome S, Sugiyama T, Inoue K, Igarashi A, Bouchi R, Ohsugi M, Ueki K, Goto A.,
Influence of the COVID-19 Pandemic on Overall Physician Visits and Telemedicine Use Among Patients With Type 1 or Type 2 Diabetes in Japan J Epidemiol

Sugimori H, Hirao M, Igarashi A, Yatsuhashi H, Ikeda S, Masaki N, Yotsuyanagi H, Yoda T, Odajima T, Takura T, Hirao T.,
Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan Sci Rep

Igarashi A, Ikeda S.,
Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interview Expert Rev Pharmacoecon Outcomes Res

Ikeda T, Igarashi A, Odani S, Murakami M, Tabuchi T.,
Health-Related Quality of Life during COVID-19 Pandemic: Assessing Impacts of Job Loss and Financial Support Programs in Japan Appl Res Qual Life

Igarashi A.,
[Current Status of Formulary in Japan and the Assessment of Various Value Components of Medicines] Yakugaku Zasshi

Igarashi A, Maruyama-Sakurai K, Kubota A, Akiyama H, Yajima T, Kohsaka S, Miyata H.,
Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan Diabetes Ther

Yang M, Awano H, Tanaka S, Toro W, Zhang S, Dabbous O, Igarashi A.,
Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy Adv Ther

Igarashi A, Ishida K, Shoji N, Chu A, Falvey H, Han R, Ueyama M, Onishi Y.,
iStent inject(®) and cataract surgery for mild-to-moderate primary open angle glaucoma in Japan: a cost-utility analysis Int J Ophthalmol

Shoji A, Kudo K, Murashita K, Nakaji S, Igarashi A.,
Reduction in medical costs for cardiovascular diseases through innovative health awareness projects in a rural area in Japan PLoS One

Kajimoto Y, Honda K, Nozawa K, Mukai M, Teng L, Igarashi A.,
Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database JCO Glob Oncol

Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, Kimura Y, Komino M, Arai H, Morikawa T, Motohashi I, Miyazawa R, Moriyama T, Kamura H, Terada M, Kuwamitsu O, Hayakawa T, Sando E, Ohara Y, Teshigahara O, Suzuki M, Morimoto K.,
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) Clin Infect Dis

Igarashi A, Hirose E, Kobayashi Y, Yonemoto N, Lee B.,
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan Expert Rev Vaccines

Mamiya H, Igarashi A.,
Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan J Med Econ

Iwata M, Oikawa Y, Shimizu Y, Sakashita N, Shoji A, Igarashi A, Osuga Y.,
Efficacy of Low-Dose Estrogen-Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis Adv Ther

Nomura A, Tanigawa T, Kario K, Igarashi A.,
Cost-effectiveness of digital therapeutics for essential hypertension Hypertens Res

Igarashi A, Nakano Y, Yoneyama-Hirozane M.,
Public preferences and willingness to accept a hypothetical vaccine to prevent a pandemic in Japan: a conjoint analysis Expert Rev Vaccines

Kiyohara Y, Matsuzaki T, Teng L, Kishida M, Kanakubo A, Motrunich A, Onishi Y, Igarashi A.,
Drug Utilization and Medical Cost Study Focusing on Moisturizers in Cancer Patients Treated with Molecular Targeted Therapy: A Retrospective Observational Study Using Data from a Japanese Claims Database Dermatol Ther (Heidelb)

Igarashi A, Kaur H, Choubey A, Popli A, Muthukumar M, Yoshisue H, Funakubo M, Ohta K.,
Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence Value Health Reg Issues

Oshima T, Igarashi A, Nakano H, Deguchi H, Fujimori I, Fernandez J.,
Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis J Clin Gastroenterol

Sekiguchi M, Igarashi A, Mizuguchi Y, Takamaru H, Yamada M, Sakamoto T, Maltzman H, Falkén Y, Esaki M, Matsuda T, Saito Y.,
Cost-effectiveness analysis of endoscopic resection for colorectal laterally spreading tumors: Endoscopic submucosal dissection versus piecemeal endoscopic mucosal resection Dig Endosc

Kajimoto Y, Shibutani T, Nagao S, Yamaguchi S, Suzuki S, Mori M, Tsubouchi H, Nakao K, Azuma A, Koyanagi T, Kohara I, Tamaki S, Yabuki M, Teng L, Honda K, Igarashi A.,
Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer Int J Gynecol Cancer

Ashizawa T, Mishina S, Igarashi A, Kobayashi T, Takase Y, Ikeda S.,
Improvement in prescriptions while maintaining overall health outcomes: a prospective observational study conducted in Japanese facilities for older people BMC Geriatr

Yoshida M, Tateishi R, Hiroi S, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A.,
Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data Adv Ther

Yoshida M, Tateishi R, Hiroi S, Hongo Y, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A.,
Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease Adv Ther

Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T.,
Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016 J Crohns Colitis

Hashimoto Y, Hayashi A, Teng L, Igarashi A.,
Real-World Cost-Effectiveness of Palliative Care for Terminal Cancer Patients in a Japanese General Hospital J Palliat Med

Ashizawa T, Igarashi A, Sakata Y, Azuma M, Fujimoto K, Kobayashi T, Takase Y, Ikeda S.,
Impact of the Severity of Alzheimer's Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan J Alzheimers Dis

Awano N, Izumo T, Inomata M, Kuse N, Tone M, Takada K, Muto Y, Fujimoto K, Kimura H, Miyamoto S, Igarashi A, Kunitoh H.,
Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis Jpn J Clin Oncol

Inoue S, Igarashi A, Iguchi Y, Akagi T.,
Cost-Effectiveness Analysis of Percutaneous Patent Foramen Ovale Closure Preventing Secondary Ischemic Stroke in Japan J Stroke Cerebrovasc Dis

Nakajima A, Shoji A, Kokubo K, Igarashi A.,
A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan Gastroenterol Res Pract

Awano N, Izumo T, Inomata M, Kuse N, Tone M, Takada K, Muto Y, Fujimoto K, Kimura H, Miyamoto S, Igarashi A, Kunitoh H.,
Medical costs of Japanese lung cancer patients during end-of-life care Jpn J Clin Oncol

Tan RL, Yang Z, Igarashi A, Herdman M, Luo N.,
How Do Respondents Interpret and View the EQ-VAS? A Qualitative Study of Three Asian Populations Patient

Igarashi A, Ueyama M, Idehara K, Nomoto M.,
Burden of illness associated with pneumococcal infections in Japan - a targeted literature review J Mark Access Health Policy

Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A.,
Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan Transplant Cell Ther

Kaneko Y, Kawahito Y, Kojima M, Nakayama T, Hirata S, Kishimoto M, Endo H, Seto Y, Ito H, Nishida K, Matsushita I, Kojima T, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, Miyasaka N, Yamanaka H.,
Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - A systematic review and meta-analysis Mod Rheumatol

Takushima Y, Igarashi A, Yoshihara H, Shitara K, Doi T.,
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan Jpn J Clin Oncol

Skrzeczek A, Ikeoka H, Hirotsu N, Ansaripour A, Aballéa S, Onishi Y, Hill M, Igarashi A.,
Cost-effectiveness of baloxavir marboxil compared to laninamivir for the treatment of influenza in Japan J Infect Chemother

Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A.,
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan Transplant Cell Ther

Mamiya H, Igarashi A.,
Determinants of market prices for drugs under Japan's national health insurance J Med Econ

Igarashi A, Bekker Hansen B, Langer J, Tavella F, Collings H, Davies N, Wyn R.,
Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment Adv Ther

Nakanishi M, Igarashi A, Ueda K, Brnabic AJM, Matsumura T, Meguro K, Yamada M, Mimura M, Arai H, Treuer T.,
Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study Curr Med Res Opin

Dronova M, Ikeoka H, Itsumura N, Hirotsu N, Ansaripour A, Aballéa S, Onishi Y, Hill M, Igarashi A.,
Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan Curr Med Res Opin

Igarashi A, Hirose E, Kobayashi Y, Yonemoto N, Lee B.,
Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan Expert Rev Vaccines

Sekiguchi M, Igarashi A, Sakamoto T, Saito Y, Esaki M, Matsuda T.,
Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score J Gastroenterol Hepatol

Igarashi A, Hunt B, Wilkinson L, Langer J, Pollock RF.,
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis Adv Ther

Kojima M, Nakayama T, Tsutani K, Igarashi A, Kojima T, Suzuki S, Miyasaka N, Yamanaka H.,
Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey Mod Rheumatol

Uda A, Eto Y, Li Y, Matsuda H, Demiya S, Watanabe T, Ota M, Iwakiri R, Igarashi A.,
Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling Crohns Colitis 360

Igarashi A, Fukuda A, Teng L, Ma FF, Dorey J, Onishi Y.,
Family caregiving in dementia and its impact on quality of life and economic burden in Japan-web based survey J Mark Access Health Policy

Ohno S, Shoji A, Hatake K, Oya N, Igarashi A.,
Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients J Med Econ

Nakanishi M, Igarashi A, Ueda K, Brnabic AJM, Treuer T, Sato M, Kahle-Wrobleski K, Meguro K, Yamada M, Mimura M, Arai H.,
Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study J Alzheimers Dis

Uda A, Eto Y, Li Y, Matsuda H, Demiya S, Watanabe T, Ota M, Iwakiri R, Igarashi A.,
Erratum: Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling Crohns Colitis 360

Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, Yoshino T, Taniguchi H.,
Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology Int J Clin Oncol

Igarashi A, Tanaka M, Abe K, Richard L, Peirce V, Yamada K.,
Cost-minimisation model of magnetic resonance-guided focussed ultrasound therapy compared to unilateral deep brain stimulation for essential tremor treatment in Japan PLoS One

Sekiguchi M, Igarashi A, Sakamoto T, Saito Y, Esaki M, Matsuda T.,
Cost-effectiveness analysis of postpolypectomy colonoscopy surveillance using Japanese data Dig Endosc

Taguchi T, Nozawa K, Parsons B, Yoshiyama T, Ebata N, Igarashi A, Fujii K.,
Effectiveness of pregabalin for treatment of chronic cervical radiculopathy with upper limb radiating pain: an 8-week, multicenter prospective observational study in Japanese primary care settings J Pain Res

Igarashi A, Furusyo N, Ogawa E, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J.,
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan BMJ Open

Igarashi A, Goto R, Yoneyama-Hirozane M.,
Willingness to pay for QALY: perspectives and contexts in Japan J Med Econ

Inoue H, Kozawa M, Milligan KL, Funakubo M, Igarashi A, Loefroth E.,
A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan NPJ Prim Care Respir Med

Miwa H, Igarashi A, Teng L, Uda A, Deguchi H, Tango T.,
Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease J Gastroenterol

Yokoya Y, Igarashi A, Uda A, Deguchi H, Takeuchi T, Higuchi K.,
Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD J Gastroenterol

Ogawa S, Hosoi T, Akishita M, Igarashi A.,
Malnutrition-Related Health Care Cost in Japan: An Analysis of Health Insurance Claims Data Asia Pac J Public Health

Miyazaki H, Igarashi A, Takeuchi T, Teng L, Uda A, Deguchi H, Higuchi K, Tango T.,
Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review J Gastroenterol Hepatol

Akazawa M, Igarashi A, Ebata N, Murata T, Zeniya S, Haga Y, Nozawa K, Fujii K, Taguchi T.,
A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan J Pain Res

Suwa K, Yoshikawa R, Iwasaki K, Igarashi A.,
The association between smoking cessation outpatient visits and total medical costs: a retrospective, observational analysis of Japanese employee-based public health insurance data J Med Econ

Igarashi A, Fukuchi Y, Hirata K, Ichinose M, Nagai A, Nishimura M, Yoshisue H, Ohara K, Gruenberger JB.,
COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan Int J Chron Obstruct Pulmon Dis

Igarashi A, Igarashi A, Graham CN, Gilloteau I, Tani Y.,
Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective J Med Econ

Tanaka Y, Yamazaki K, Nakajima R, Komatsu S, Igarashi A, Tango T, Takeuchi T.,
Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study Mod Rheumatol

Kimura T, Igarashi A, Ikeda S, Nakajima K, Kashimura S, Kunitomi A, Katsumata Y, Nishiyama T, Nishiyama N, Fukumoto K, Tanimoto Y, Aizawa Y, Fukuda K, Takatsuki S.,
A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS(2) score in Japan J Cardiol

Yoshikawa R, Igarashi A, Goto R, Suwa K.,
[Attitudes towards passive smoking at restaurants and effects of the provision of information: A comparison between smokers and non-smokers via a web survey] Nihon Koshu Eisei Zasshi

Kojima M, Nakayama T, Otani T, Hasegawa M, Kawahito Y, Kaneko Y, Kishimoto M, Hirata S, Seto Y, Endo H, Ito H, Kojima T, Nishida K, Matsushita I, Tsutani K, Igarashi A, Kamatani N, Miyasaka N, Yamanaka H.,
Integrating patients' perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan Mod Rheumatol

Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, Igarashi A, Tango T, Tanaka Y.,
Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study Adv Ther

Xie F, Pullenayegum E, Pickard AS, Ramos Goñi JM, Jo MW, Igarashi A.,
Transforming Latent Utilities to Health Utilities: East Does Not Meet West Health Econ

Feng Y, Herdman M, van Nooten F, Cleeland C, Parkin D, Ikeda S, Igarashi A, Devlin NJ.,
An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D Qual Life Res

Suwa K, Flores NM, Yoshikawa R, Goto R, Vietri J, Igarashi A.,
Examining the association of smoking with work productivity and associated costs in Japan J Med Econ

Igarashi A, Tang W, Guerra I, Marié L, Cure S, Lopresti M.,
Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan Curr Med Res Opin

Igarashi A, Tang W, Cure S, Guerra I, Marié L, Lopresti M, Tsutani K.,
Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan Curr Med Res Opin

Hoshi D, Tanaka E, Igarashi A, Inoue E, Kobayashi A, Sugimoto N, Shidara K, Sato E, Seto Y, Nakajima A, Momohara S, Taniguchi A, Tsutani K, Yamanaka H.,
Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database Mod Rheumatol

Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, Shimozuma K.,
Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan Value Health

Fukuda A, Igarashi A.,
[Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective] Gan To Kagaku Ryoho

Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S, Shimozuma K.,
Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D Qual Life Res

Igarashi A, Inoue S, Ishii T, Tsutani K, Watanabe H.,
Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension Int Heart J

Igarashi A, Goto R, Suwa K, Yoshikawa R, Ward AJ, Moller J.,
Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation Appl Health Econ Health Policy

Virabhak S, Yasui K, Yamazaki K, Johnson S, Mitchell D, Yuen C, Samp JC, Igarashi A.,
Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan J Med Econ

Sekiguchi M, Igarashi A, Matsuda T, Matsumoto M, Sakamoto T, Nakajima T, Kakugawa Y, Yamamoto S, Saito H, Saito Y.,
Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data Jpn J Clin Oncol

Kojima M, Nakayama T, Kawahito Y, Kaneko Y, Kishimoto M, Hirata S, Seto Y, Endo H, Ito H, Kojima T, Nishida K, Matsushita I, Tsutani K, Igarashi A, Kamatani N, Hasegawa M, Miyasaka N, Yamanaka H.,
The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: Utilization of GRADE approach Mod Rheumatol

Sakakibara M, Igarashi A, Takase Y, Kamei H, Nabeshima T.,
Effects of Prescription Drug Reduction on Quality of Life in Community-Dwelling Patients with Dementia J Pharm Pharm Sci

Sakakibara M, Kido M, Kuribayashi J, Okada H, Igarashi A, Kamei H, Nabeshima T.,
Comparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer's Disease Patients Clin Psychopharmacol Neurosci

Ito H, Kojima M, Nishida K, Matsushita I, Kojima T, Nakayama T, Endo H, Hirata S, Kaneko Y, Kawahito Y, Kishimoto M, Seto Y, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, Miyasaka N, Yamanaka H.,
Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis Mod Rheumatol

Kaitani T, Nakagami G, Iizaka S, Fukuda T, Oe M, Igarashi A, Mori T, Takemura Y, Mizokami Y, Sugama J, Sanada H.,
Cost-utility analysis of an advanced pressure ulcer management protocol followed by trained wound, ostomy, and continence nurses Wound Repair Regen

Igarashi A, Akazawa M, Murata T, Taguchi T, Sadosky A, Ebata N, Willke R, Fujii K, Doherty J, Kobayashi M.,
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan Clinicoecon Outcomes Res

Taguchi T, Igarashi A, Watt S, Parsons B, Sadosky A, Nozawa K, Hayakawa K, Yoshiyama T, Ebata N, Fujii K.,
Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan J Pain Res

Suka M, Odajima T, Okamoto M, Sumitani M, Igarashi A, Ishikawa H, Kusama M, Yamamoto M, Nakayama T, Sugimori H.,
Relationship between health literacy, health information access, health behavior, and health status in Japanese people Patient Educ Couns

Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K.,
Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency Clin Ther

Igarashi A.,
[Pharmacoeconomics of molecular targeting drugs] Nihon Rinsho

Igarashi A, Fujito K, Hirano M, Fukuda T.,
Cost minimization analysis of beta-blocker at the time of CT imaging for suspected of coronary heart disease in Japan J Med Econ

Igarashi A, Negishi S, Goto R, Suwa K.,
Web-based survey on smoking cessation behaviors of current and former smokers in Japan Curr Med Res Opin

Kogure T, Sumitani M, Suka M, Ishikawa H, Odajima T, Igarashi A, Kusama M, Okamoto M, Sugimori H, Kawahara K.,
Validity and reliability of the Japanese version of the Newest Vital Sign: a preliminary study PLoS One

Hashimoto Y, Igarashi A, Miyake M, Iinuma G, Fukuda T, Tsutani K.,
Cost-Effectiveness Analysis of CT Colonography for Colorectal Cancer Screening Program to Working Age in Japan Value Health Reg Issues

五十嵐中, 佐條麻里. わかってきたかも医療統計 だけど論文読めません!! 東京図書, 2016.

鶴岡浩樹, 津谷喜一郎. 補完代替医療(CAM)総論. In: 八木剛平, 渡邊衡一郎(編). レジリアンス－症候学・脳科学・治療学. 金原出版, 2014.p.206-19

津谷喜一郎, 五十嵐中. 関節リウマチ診療ガイドライン 2014 と経済評価. In:一般社団法人日本リウマチ学会(編). 関節リウマチ診療ガイドライン 2014. メディカルレビュー社, 2014. p.116-20.

五十嵐中, 佐條麻里. 薬剤経済わかりません!! 東京図書, 2014.

Tang W, Tsutani K. Pharmacoeconomic evaluations on Kampo medicine and development of structured abstracts. In: Motoo Y(ed). Traditional Medicine: New Research. Nova Science Publishers, 2013.p.180-90.

Tsutani K, Hikiami H, Satake M,Toriizuka K, Yamada K. Appendix: Standard kampo formula nomenclature. In: Motoo Y(ed). Traditional Medicine: New Research. Nova Science Publishers, 2013.p.239-45.

国立大学法人東京大学大学院薬学系研究科医薬政策学, 一般財団法人医療経済研究・社会保険福祉協会. 「健康食品の制度化への障壁に関する研究」共同研究最終報告書, 2013.

津谷喜一郎. 日本のエビデンスに基づく医療（EBM）の動きからのレッスン. In: 教育政策研究所（編）. 教育研究とエビデンス　国際的動向と日本の現状と課題. 明石書店, 2012.p.185-203.

津谷喜一郎. アンメット・メディカルニーズ. 薬剤経済学. エンドポイント. コンパッショネート使用. In: 笠原忠, 木津純子, 諏訪俊男（編）. 新しい薬学事典. 明石書店, 2012.p.340-56.

五十嵐中, 佐條麻里, 高瀬義昌. わかってきたかも!?「医療統計」. 東京図書; 2012.

李博, 柳平貢, 張夢転, 米良彰子, 津谷喜一郎 (訳). 公衆衛生におけるR&Dの危機に終止符を：貧困克服の医療イノベーションを促進しよう. Oxfam Briefing Paper; 2011〔原著: Ending the R&D Crisis in Public Health. Oxfam Briefing Paper; 2008〕

『公衆衛生におけるR&Dの危機に終止符を』日本語版公表. Oxfam Japan-News & Topics.

津谷喜一郎 (著). CONSORT 声明. In: 日本臨床薬理学会（編）. 臨床薬理学 第３版. 医学書院; 2011. p.72-4.

寺岡章雄, 津谷喜一郎 (著). 日本で承認されていない薬を安全に使う：コンパッショネート使用制度. 日本評論社; 2011.

孫一善 (著). 韓国の医療制度と医薬品流通. ライフサイエンス出版; 2011.

五十嵐中, 佐條麻里. 「医療統計」わかりません!!. 東京図書; 2010.

津谷喜一郎 (監訳). 鍼のエビデンス 増補改訂版: 鍼灸臨床評価論文のアブストラクト. 医道の日本社; 2009.

特別用途食品および栄養療法のエビデンス等に関する情報の収集整理業務平成20年度報告書 (特別用途食品エビデンスレポート2008).

津谷喜一郎, Beresniak A (編). 薬剤経済学の活用. ー医薬品の経済的エビデンスをつくる・つかうー. エルゼビア・ジャパン; 2008.

陸寿一, 津谷喜一郎 (監訳). 欧州ジェネリック市場の持続発展. 日本ジェネリック製薬協会; 2008. 〔原著: Simones S, Coster SD. Sustaining generic medicines markets in Europe. Lueven, Netherland: Katholieke Universiteit Lueven; 2006.〕

津谷喜一郎, 渡邉裕司 (編著). ケーススタディから学ぶ医療政策 : エビデンスからポリシーメーキングへ. ライフサイエンス出版; 2007.

津谷喜一郎, 内田英二 (編著). くすりをつかう エビデンスをつかう. 中山書店; 2007.

津谷喜一郎 (編). くすりギャップ: 世界の医薬品問題の解決を目指して. ライフサイエンス出版; 2007.

杉山雄一, 津谷喜一郎 (編). 医薬品開発戦略: 臨床薬理に基づく. 廣川書店; 2006.

津谷喜一郎, 内田英二 (編著). くすりとエビデンス: 「つくる」＋「つたえる」. 中山書店; 2005.

津谷喜一郎 (監訳). ファーマコジェネティクス -薬物治療の改善を目指して. テクノミック; 2005. 〔原著: Council for International Organizations of Medical Sciences. Pharmacogenetics-Toward improving treatment with medicines. Geneva, Council for International Organizations of Medical Sciences; 2005.〕

津谷喜一郎, 高原亮二 (監訳). エビデンスに基づくヘルスケア: ヘルスポリシーとマネージメントの意思決定をどう行うか. エルゼビア・ジャパン; 2005. 〔原著: Muir Gray JA. Evidence‐based healthcare: how to make health policy and management decisions, second edition. London: Churchill Livingstone; 2001.〕

内山充 (監修), 津谷喜一郎 (編). レギュラトリーサイエンスの発展: 官・学・産のフォーラムを目指して. エルゼビア・ジャパン; 2004.

舟喜光一, 津谷喜一郎 (訳). ランダム化比較試験: 100のquestionsに学ぶ. じほう; 2004. 〔原著: Jadad AR. Randomised controlled trials: a user's guide. London: BMJ books; 1998.〕

津谷喜一郎. 医薬品の適応外使用: 20世紀末のエビデンス. ライフサイエンス出版; 2004.

西田在賢 (編著), 福田敬, 橋本英樹, 他 (著). 新時代に生きる医療保険制度: 持続への改革論. 薬事日報社; 2004.

津谷喜一郎 (監訳). 鍼のエビデンス: 鍼灸臨床評価論文のアブストラクト. 医道の日本; 2003.

津谷喜一郎 (編). 世界の鍼灸コミュニケーション. 全日本鍼灸学会国際部; 2003.

津谷喜一郎. WHOと伝統医学. 自家出版, 2003.

津谷喜一郎, 津富宏, 正木朋也. 人文社会科学でも実験は可能だ: キャンベル共同計画と政策評価の現状と将来. 東京大学大学院薬学系研究科医薬経済学; 2003.

福田敬 (監修). 薬局機能評価マニュアル 改訂第2版. じほう; 2003.

福田敬 (監修). 薬局機能評価マニュアル. じほう; 2002.

清水直容, 津谷喜一郎 (編). 一般用医薬品と伝統薬の臨床評価: Clinical evaluation of OTC drugs and traditional drugs. デジタルプレス; 2001.

Yoshihara H. A label noise robust ISUP grading system using multi-instance learning. MICCAI 2020 Workshop, 08 Oct 2020.

Igarashi A. Basic concept of QALY and its implementation to QALY -beyond “urban myth”. HTAi 2016 Annual Meeting Tokyo Japan, 13 May 2016.

R Watanabe, A Igarashi, H Wakamoto, H Osawa. A Cost-Minimization Analysis of Dermatophyte Test Kit with Onychomycosis Under Health Care System in Japan. ISPOR 19th Annual European Congress. November 2016; Vienna, Australia. Poster presentation.

K Suwa, R Yoshikawa, A Igarashi, R Goto, J Vietri, NM Flores. Benefits of Quitting Smoking in Japan on Working Productivity and Activity Impairment and Indirect Costs. ISPOR 19th Annual European Congress. November 2016; Vienna, Australia. Poster presentation.

S Noto, R Izumi, K Moriwaki, T Shiroiwa, A Igarashi, T Fukuda, S Ikeda, S Saito. Comparison Between Eq-5d And Hui In Japanese Population Norms. ISPOR 19th Annual European Congress. November 2016; Vienna, Australia. Poster presentation.

M Sasaki, T Fukuda, T Shiroiwa, A Igarashi, H Sato. Trends in Japanese Clinical Trial Registration from 2005 to 2014. ISPOR 19th Annual European Congress. November 2016; Vienna, Australia. Poster presentation.

T Fukuda, A Igarashi, H Ishida, S Ikeda, S Saito, H Sakamaki, K Shimozuma, T Shiroiwa. Economic Evaluation Guideline for Pharmaceuticals and Medical Devices in Japan. ISPOR 19th Annual European Congress. November 2016; Vienna, Australia. Poster presentation.

A Igarashi, Y Fukuchi, K Hirata, M Ichinose, A Nagai, M Nishimura, N Lara, S Murata. COPD Uncovered: Health Care Resource Use and Cost of Chronic Obstructive Pulmonary Disease in Japan. ISPOR 19th Annual European Congress. November 2016; Vienna, Australia. Poster presentation.

Igarashi A. Current status of Public health and the role of HTA in Japan. Enhancement of Regional Health in East Asia with Special Reference to the Public Health and Universal Health Coverage. Tokyo, 6 Jul. 2016.

Igarashi A. Enhansing of Regional Health in East Asia with Special Reference to the Public Health and Universal Health Coverage. The 25th Network of East Asia Think Tanks (NEAT) Country Coordinators Meeting, Bangkok, Thailand, 28 Jul. 2016.

Igarashi A. Japan HTA: Impact of HTA guidelines in Japan in 2016. 2nd Annual Market Access in Asia. Singapore. 3 Aug. 2016.

Igarashi A. EQ-5D value set studies in Japan: its implementation to JP-HTA system. EQ-5D symposium for Policy makers and HTA practitioners in Asia, Singapore, 4 Sep. 2016.

Igarashi A. Economic Evaluation for pricing reimbursement: Current Japanese situation. Takeda Pharmaceuticals ISPOR Advisory Board Meeting, Singapore, 4 Sep. 2016.

五十嵐中. 予防介入の中での禁煙介入の費用対効果. FCTC班成果発表会, 東京, 2016.1.18. 14. 五十嵐中. 新規 C 型肝炎治療薬の医療経済的価値. 第 362 回福山市医師会消化器病研究会, 福山, 2016.1.19.

五十嵐中. 女性の健康増進の社会経済的影響. 働く女性の健康増進に関する調査 メディアセミナ ー. 東京, 2016.1.20.

池田俊也, 五十嵐中. HPV ワクチンの費用効用分析. 平成 27 年度日本医療研究開発機構研究費「Hib、肺炎球菌、HPV 及びロタウイルスワクチンの各ワクチンの有効性、安全性並びにその投与方 法に関する基礎的・臨床的研究」第 2 回班会議, 東京, 2016.1.30.

五十嵐中. HTA試行導入を前に考える C型肝炎インターフェロンフリー治療薬の費用対効果. アッ ヴィ合同会社 メディアラウンドテーブル, 東京, 2016.2.4.

五十嵐中. EBM 時代の薬剤経済学. 大阪大学臨床医工学融合研究教育センター クリニカルリサ ーチプロフェッショナルコース「医薬品の市場とライフサイクルマネジメント」, 東京, 2016.2.20.

五十嵐中. 数字の読み方わかりません! 統計入門. RIHDS 養成講座, 東京, 2016.4.14.

五十嵐中. RA 治療ガイドラインにおける医療経済評価の位置づけと日本での展望. 第 60 回日本リ ウマチ学会総会学術集会, 横浜, 2016.4.23.

五十嵐中. 禁煙治療の費用対効果とは？ 第 5 回禁煙治療研究会, 京都, 2016.5.29.

五十嵐中. HTAの基礎と最新動向. 日本医療政策機構 第 58 回定例朝食会, 東京, 2016.6.2.

五十嵐中. 数字の読み方わかりません. 第 3 回薬物治療連携研究会, 金沢, 2016.6.5.

五十嵐中. 費用対効果評価・価格への利活用 フランスの現状を踏まえて. 薬剤経済学研究会 20 周年記念講演会, 東京, 2016.6.7.

五十嵐中. 医療のムダって何のこと？ 第 123 回東京大学公開講座, 東京, 2016.6.11.

五十嵐中. 新規 C 型肝炎治療薬の医療経済的評価から見えてきた薬の価値. HCV Lecture Meeting, 川崎, 2016.6.15.

五十嵐中. 受動喫煙防止等のたばこ対策による経済面の効果評価とモデル構築. 平成 28 年度厚 生労働科学研究費補助金「受動喫煙防止等のたばこ対策の推進に関する研究 」第 1 回班会議, 東京, 2016.8.12.

五十嵐中, 滕麗達, 大塚裕次朗, 岩崎宏介, 丹後俊郎. 胃食道逆流症患者に対するボノプラザン の治癒効果における PPI との比較: ネットワークメタアナリシスによる検討. ISPOR 日本部会 第 12 回学術集会, 東京, 2016.8.31.

五十嵐中. くすりの費用対効果とは? 海外の情勢と日本の今後. 第 26 回日本医療薬学会 ランチョ ンセミナー, 京都, 2016.9.18.

五十嵐中. 経済評価研究の進め方. 薬剤経済学研究会勉強会, 熱海, 2016.9.20.

五十嵐中, 大西佳恵. レセプトデータ分析. RIHDS 講習会, 東京, 2016.10.13.

五十嵐中. HTA (医療技術評価)とその政策応用. 日本製薬工業協会産業政策委員会勉強会, 東 京, 2016.10.14.

五十嵐中. 医薬品とワクチンの費用対効果評価. EFPIA ワクチン部会勉強会, 東京, 2016.10.25.

五十嵐中. 予防介入の中での禁煙介入の費用対効果. 日本公衆衛生学会年会 シンポジウム 14 「たばこ規制の推進に役立つエビデンスの構築と政策実現に向けたアドボカシー」 大阪, 2016.10.27.

五十嵐中. 私と禁煙, 禁煙と私. 第 11 回日本禁煙科学会シンポジウム, 京都, 2016.10.29.

五十嵐中. COPDの医療経済とは？2016 年COPDサミット, 東京, 2016.11.9. 37. 五十嵐中. HTA試行導入の最新動向. 第 13 回DIA 年会, 東京, 2016.11.14.

五十嵐中. スウェーデンの看護領域でのHTAの活用実態. 第 7 回看護経済政策研究学会, 東京, 2016.11.19.

五十嵐中. 医療経済評価と在宅医療機器. 在宅医療機器勉強会, 東京, 2016.11.24.

五十嵐中. 抗がん剤の費用対効果とは? がん患者学会 2016, 東京, 2016.12.2.

五十嵐中. 受動喫煙防止等のたばこ対策による経済面の効果評価とモデル構築. 平成 28 年度厚 生労働科学研究費補助金「受動喫煙防止等のたばこ対策の推進に関する研究 」第 2 回班会議, 東京, 2016.12.2.

五十嵐中. 医療費とガイドライン. 日本肺癌学会シンポジウム, 福岡, 2016.12.20.

五十嵐中. 配合剤の費用対効果. 第 38 回日本高血圧学会総会. 松山, 2015.10.9. 2.

Igarashi A. Market Access in Japan. EMAUD. Paris, 7 Oct. 2015.

Igarashi A, Fukuda T, Kobayashi M, et al. Development of a national tariff for EQ-5D-5L in Japan. 32nd EuroQOL plenary meeting, Krakov, Poland; 10 Sep. 2015.

五十嵐中. 介助者向け「認知症疑い」チェックアプリとは？ 認知症フレンドリージャパン サミット, 2015. 東京, 2015.9.5.

五十嵐中. 費用対効果評価における問題点および将来の発展. SAS ユーザー総会 2015. 東京, 2015.8.7.

五十嵐中. 医療経済学的アプローチの基礎. レギュラトリーサイエンス財団 メディカルア フェアーズエキスパート研修講座. 東京, 2015.7.27.

五十嵐中. がん治療・粒子線治療の費用対効果. 日本放射線腫瘍学研究機構特別講演会. 東 京, 2015.7.25.

五十嵐中. 尿路悪性腫瘍治療の費用対効果とは?. 第 42 回尿路悪性腫瘍研究会. 東京, 2015.7.18.

五十嵐中. ブラウンバッグ運動これまでとこれから. 山形県薬剤師会講演会. 山形, 2015.7.12.

Igarashi A. Japanese result of Asian valuing study. A workshop on Cost-effectiveness Thresholds; Conceptualization and Estimation. London, 26 Jun 2015.

五十嵐中. バイオシミラーの費用対効果. 第 9 回日本ジェネリック医薬品学会学術大会. 浜 松, 2015.6.14.

五十嵐中. 認知症ケアのエビデンスを「つくる」-関連施設での調査研究の結果から. IT ヘル スケア学会 第 9 回学術大会. 熊本, 2015.6.7.

Igarashi A, Goto R, Yoshikawa R, et al. Cost-effectiveness analysis of smoking cessation interventions in Japan using the discrete event simulation model. ISPOR 20th Annual International Meeting. Philadelphia, USA, 18 May 2015. Value in Health 2015: 18 (3): A174.

Sekiguchi M, Matsuda T, Igarashi A, et al. What is the optimal use of total colonoscopy in colorectal cancer screening? : A cost-effectiveness analysis using Japanese data. Digestive Disease Week 2015. Washington DC, 17 May 2015. Gastroenterology 2015: 148 (4): S743-4.

Igarashi A. PE studies for RA treatment & QOL in Japanese RA patients. 5th Hangyang University Hospital for Rheumatic Diseases International Symposium. Seoul, 14 May 2015.

五十嵐中. 経済評価の政策応用 アセスメント・アプレイザル・ディシジョン. 第 29 回日本 医学会総会, 京都, 2015.4.11.

五十嵐中, 嶋元, 渡邉普,他. クラウドベースの電子お薬手帳"harmo"システムの開発と川崎市 での社会実験. 日本薬学会第 135 年会. 神戸, 2015.3.25.年会要旨集 p. 64.

五十嵐中. 日本語版 EQ-5D-5L タリフの開発. 新潟医療福祉大学 医療経済・QOL 研究セン ター 第 2 回セミナー「わが国における医療経済評価の実際と政策への応用」. 新潟, 2015.2.21.

五十嵐中, 榊原幹夫, 髙瀬義昌, 他. プライマリ・ケア領域で適応可能な認知症スクリーニン グアンケートの開発. 日本薬学会第 135 年会. 神戸, 2015.3.25.年会要旨集 p. 158.

Igarashi A. What should we do for HTA in Japan. Japan HTA workshop in Astellas Pharma. Tokyo, 19 Feb. 2015.

五十嵐中. 薬局と薬局薬剤師の役に立ち方は? 第 3 回医薬品適正使用協働研究会, 東京. 2015.2.4.

五十嵐中. 海外の医療経済評価. レギュラトリーサイエンス財団 メディカルアフェアーズ

矢野智代, 津谷喜一郎. 笑いを介入としたランダム化比較試験のシステマティック・レビュー-笑いとくすりはどちらが効くか？-. 日本薬学会第134回年会, 熊本, 2014.3.28.

Kitamura K. Tsutani K. Kitagawa M. The Japanese Association of Medical Journal Edditors. APAME2014, Ulaanbaatar. 2014.8.15-17.

福澤学, 唐文涛, 小池竜司, 石川ひろの, 木内貴弘, 津谷喜一郎. 日本の臨床試験の登録は被験者の組み入れ前に行われているか？‐UMIN-CTR登録情報から‐. 日本薬学会第134回年会, 熊本, 2014.3.28.

増島祥, 正木朋也, 唐文涛, 津谷喜一郎. 日本と世界におけるクラスターランダム化比較試験の現状と課題. 第34回日本臨床薬理学会学術総会, 東京, 2013.12.4.

寺岡章雄. 薬剤師のプロフェッショナリズムと医薬分業−患者に真に役立つ医薬分業の実現を志向して−. 日本社会薬学会第32年会, 町田, 2013.10.14.

津谷喜一郎. 「もっと早く病・医院へ行けばよかった」アンケート調査概要-平成24年度厚生労働科学研究による代替医療の間接的健康被害研究より-. 第2回エビデンスに基づく統合医療研究会（eBIM研究会）, 大阪, 2013.8.11.

寺岡章雄, 津谷喜一郎. ドライ系薬学領域の学会誌から見るディシプリンの動向と課題. 日本薬学会第133年会, 横浜, 2012.3.30.

津谷喜一郎. 抗するCAMか合するCAMか-共通言語としてのエビデンス-. 第1回エビデンスに基づく統合医療研究会（eBIM研究会）, 大阪, 2012.7.19.

津谷喜一郎. ファーマコビジランス-薬剤疫学的手法について-. 第20回薬害肝炎事件の検証及び再発防止のための医薬品行政のあり方検討会. 2010.1.18　　議事録　　資料

柳平貢, 津谷喜一郎. 見捨てられた疾患に対する海外での医薬品開発インセンティブの日本への応用. 日本薬学会第132年会, 札幌, 2012.3.30.

根岸辰太朗, 津谷喜一郎. 偽造医薬品に対する製薬企業の取り組み. 日本薬学会第132年会, 札幌, 2012.3.30

Tsutani K. Health claim and evidence in health food in Japan: vocabulary and law. International Conference and Exhibition on Nutraceuticals and Functional foods, Sapporo, 16 Nov. 2011.

Tsutani K. Physician-Pharmaceutical Industry Interaction: Japanese Experiences. The Korean Society for Medical Ethics Bi-Annual Conference 2010, Seoul, ROK, 30 Oct. 2010.

Tsutani K. Conflict of Interest in Japan. The Korean Society for Medical Ethics Bi-Annual Conference 2010, Seoul, ROK, 30 Oct. 2010.

Tsutani K. History of traditional east Asian medicine (TEAM). Japanese delegation to International Seminar on "TCM" (provisional)
Standardization, Shanghai, 25 Jan. 2010.

Igarashi A, Kikuta K, Hoshi D, Tanaka E, Yamanaka H, Tsutani K. Conjoint analysis of reduction of co-payment rate of national health insurance system in Japan. ISPOR 13th Annual European Congress, Prague, Czech, 7 Nov. 2010.

Igarashi A, Kikuta K,Tanaka E, Hoshi D, Inoue E, Seto Y, Nakajima A, Momohara S, Taniguchi A, Yamanaka H, Tsutani K. Analysis of direct medical and non-medical costs for care of rheumatoid arthritis patients using large cohort database, IORRA. ISPOR 13th Annual European Congress, Prague, Czech, 7 Nov. 2010.

津谷喜一郎. ファーマコゲノミクス検査の医療経済学からの考察. 日本人類遺伝学会第55回大会, さいたま, 2010.10.28. 日本人類遺伝学会第55回大会抄録集, 2010: 87.

菊田健太郎, 五十嵐中, 大濱宏文, 池田秀子, 斎場仁, 津谷喜一郎. 健康食品は医療費を低減するか？−米国のLewin研究を批判的に読む−. 第69回日本公衆衛生学会総会, 東京, 2010.10.27-29.

橋本義彦, 津谷喜一郎. 天然痘根絶計画から学ぶこと：費用対効果の観点から. 第25回日本国際保健医療学会学術大会, 福岡, 2010.9.11-12. / Hashimoto Y,Tsutani K. Lessons from Smallpox Eradication Programs: thinking about the programs in terms of cost-effectiveness. Journal of International Health (国際医療保健) 2011; 26(3): 236.

五十嵐中, 正木朋也, 佐々木亮, 橋本義彦, 津谷喜一郎. 殺虫剤処理済蚊帳は費用対効果に優れるか？-貧困アクションラボによるBest Buyプロジェクトの批判的吟味-. 第25回日本国際保健医療学会学術大会, 福岡, 2010.9.11-12. / Igarashi A, Tomoya M, Sasaki R, Hashimoto Y, Tsutani K. Are the insecticide treated nets cost effective?: Critical appraisal of MIT J-PAL "Best Buy" recommendations. Journal of International Health (国際医療保健) 2011; 26(3): 235.

津谷喜一郎. 倫理の視点から. 第2回東京大学メディカルキューブシンポジウム「社会に開かれたトランスレーショナルリサーチの推進を目指して」, 東京, 2010.7.5.

加藤陽, 五十嵐中, 牧田比呂仁, 福田敬, 西村正治, 津谷喜一郎. 日本における慢性閉塞性肺疾患の医療経済評価モデルの構築. 日本薬学会第130年会, 岡山, 2010.3.30.

陳鋒, 草間真紀子, 津谷喜一郎. 中国・日本・米国における医薬品副作用/有害事象報告. 日本薬学会第130年会, 岡山, 2010.3.30.5

津谷喜一郎. ファーマコビジランス. -薬剤疫学的手法について-. 第20回薬害肝炎の検証及び再発防止のための医薬品行政のあり方検討委員会, 2010.1.18

Igarashi A, Fukuda T, Orihara S, Suzuki H, Tsutani K. Cost-utility analysis of rota virus vaccine (rotarix®) in Japan. ISPOR 12th Annual European Congress, Paris, France. 26 October 2009.

Tsutani K, Yaju Y, Sato Y, et al. Sharp increase of the access to the Japanese translations of Cochrane systematic reviews' abstracts after the introduction of non-login system. 17th Cochrane Colloquium, Singapore, 13 October 2009.

張夢耘, 元雄良治, 津谷喜一郎. 漢方薬・中薬の診療ガイドラインにおける日中比較. 第30回日本臨床薬理学会年会. 横浜, 2009.12.3.

李博, 張夢耘, 米良彰子, 津谷喜一郎. 見捨てられた疾患に対する医薬品パテント制度以外の解決法はあるか? 第24回国際保健医療学会学術大会, 仙台, 2009.8.6. 国際保健 2009; 24 suppl: 132,

平 成人、澤木 正孝、下妻 晃二郎、高橋 都、福田 敬、白岩 健、田中 夕香理、枝園 忠彦、土井原博義、大橋 靖雄. HER2陽性高齢者乳癌に対する術後補助療法に関するTrastuzumabと化療併用のRCT:N-SAS BC07 QOL pilot試験. 第17回日本乳癌学会学術総会. 東京, 2009.7.3. 日本乳癌学会総会プログラム抄録集 2009: 435.

五十嵐中, 星大介, 折原慎弥, 山中寿, 津谷喜一郎, 他. RA患者のQOLスコア (EQ-5Dスコア)に影響する因子の解析 -IORRAコホートにおける検討-. 第53回日本リウマチ学会総会・学術集会, 東京. 2009.4.23.

星大介, 五十嵐中, 津谷喜一郎, 山中寿, 他. EQ-5DはRA患者の身体機能障害を反映したQOL指標である -IORRAコホートにおける解析より-. 第53回日本リウマチ学会総会・学術集会, 東京, 2009.4.23.

折原慎弥, 五十嵐中, 鈴木宏, 福田敬, 津谷喜一郎. 日本におけるロタウイルスワクチンの薬剤経済分析. 第129回日本薬学会年会, 京都, 2009.3.26.

折原慎弥, 五十嵐中, 鈴木宏, 福田敬, 津谷喜一郎. 日本におけるロタウイルスワクチンの薬剤経済分析. 第129回日本薬学会年会, 京都, 2009.3.26 日本薬学会第129年会抄録集 2009.

田中康裕, 津谷喜一郎. Pharmacogeneticsの安全性, 有効性, 経済性評価におけるNNTとNNSの役割. 第129回日本薬学会年会, 京都, 2009.3.26.

田中康裕, 津谷喜一郎. Pharmacogeneticsの安全性, 有効性, 経済性評価におけるNNTとNNSの役割. 第129回日本薬学会年会, 京都, 2009.3.26. 日本薬学会第129年会抄録集 2009.

Igarashi A, Hoshi D, Orihara S, Yamanaka H, Tsutani K, et al. Major determinants of euroqol (EQ-5D) with rheumatoid arthritis based on a large japanese cohort IORRA. ISPOR 11th Annual European Congress, Athens, Greece. 8 Nov. 2008. Value in Health 2008; 11 (6): 218.

Hoshi D, Igarashi A, Tsutani K, Yamanaka H, et al. EuroQoL (EQ-5D) based QOL (quality of life) in 5,023 Japanese patients with rheumatoid arthritis (RA) patients in an observational cohort IORRA. ISPOR 11th Annual European Congress, Athens, Greece. 8 Nov. 2008. Value in health 2008; 11 (6): 220.

Beresniak A, Auguier P, Tsutani K, et al. International development of the first quality of life instrument specific to cosmetology and physical appearance : the beautyqol initiative. ISPOR 13th Annual International Meeting, Toronto, Canada, 6 May 2008.

Igarashi A, Fukuda T, Tsutani K. Cost-utility analysis of varenicline, an oral smoking cessation drug, in Japan. ISPOR 13th Annual International Meeting, Toronto, Canada, 6 May 2008.

Shiroiwa T, Sung YK, Fukuda T, Bae SC, Tsutani K. International survey on WTP for one additional QALY gained -what is the threshold of cost-effectiveness? ISPOR 13th Annual International Meeting, Toronto, Canada, 6 May 2008. Value in Health 2008; 11 (3): A179.

青木洋子, 久保盛裕, 陸寿一, 津谷喜一郎. フランスのジェネリック医薬品使用急伸における医師・薬剤師・患者・疾病金庫の役割. 第29回日本臨床薬理学会年会, 東京, 2008.12.6. 臨床薬理 2008; 39 (Suppl): S307.

陸寿一, 久保盛裕, 青木洋子, 津谷喜一郎. フランスのジェネリック医薬品使用急伸における薬局への経済的インセンティブ要因. 第29回日本臨床薬理学会年会, 東京, 2008.12.6. 臨床薬理　2008; 39 (Suppl): S307.

花房伊保里, 津谷喜一郎, 小池竜司. ヘルシンキ宣言2000年エジンバラ修正版がプラセボ対照試験に与えた影響. 第29回日本臨床薬理学会年会, 東京, 2008.12.6. 臨床薬理 2008; 39 (Suppl): S279.

辻香織, 津谷喜一郎. 臨床的重要度の高い新医薬品のドラッグラグ−重篤稀少疾患の開発着手遅延が最大の問題−. 第29回日本臨床薬理学会年会, 東京, 2008.12.5.

毛利 光子, 千葉 康司, 白岩 健, 福田 敬, 大橋 靖雄, 諏訪 俊男.転移性乳がん治療におけるBevacizumabの薬剤経済学的評価. 第29回日本臨床薬理学会年会. 東京, 2008.12.4. 臨床薬理 2008 39(Suppl): S209.

五十嵐中. コンジョイント分析を用いたたばこ税収試算. 第3回日本禁煙科学会学術集会, 東京, 2008.11.15.

津谷喜一郎. お金と効き目と好みからみた健康食品の位置づけ. 第15回 健康食品フォーラム報告書「健康食品の存在意義〜代替医療の進展する中で〜」. 東京, 2008.10.2.

津谷喜一郎. 医学雑誌のアクセスと質向上のための世界の動き: GHL/WPRIMとAPAME. 第1回日本医学雑誌編集者会議 (JAMJE) シンポジウム, 東京, 2008.8.1.

小山紘一, 津谷喜一郎. 日本でのランダム化比較試験における封筒法の興亡. 日本薬学会第128回年会, 横浜, 2008.3.27.

澤田弘, 津谷喜一郎. How do we Interpret the Evidences from Large-scale Clinical Trials of Cardiovascular Diseases for the Development of Clinical Practice Guidelines? 第72回日本循環器学会総会・学術集会, 2008.3.28, 福岡. Circ J 2008; 72 Suppl 1.

Tsutani K, Tu Y. The history and current situation of the classification of traditional Chinese medicine in China and Kampo drugs in Japan. The 14th International Congress of Oriental Medicine (14thICOM) Taipei, 3 December 2007.

Tsutani K, Fei Y, Oishi Y, Tu Y, Liu J. Comparison of clinical trial registry systems and registered trials between Japan and China. The 3rd China-Japan joint meeting of basic and clinical pharmacology, Dalian, China, 24 Aug 2007. 中国薬理学雑誌 (Chinese journal of pharmacology and toxicology) 2007; 21 (4): 339.

折原慎弥， 津谷喜一郎. だれでもアクセスできるランダム割付けソフトLatin390の開発． 第27回日本臨床薬理学会年会. 2007.11.30, 宇都宮. 臨床薬理 2007; 38 Suppl: S306 (ver. 1.1).

折原慎弥，津谷喜一郎. 診療ガイドラインにおける遺伝子検査の扱い． 第27回日本臨床薬理学会年会. 2007.11.30, 宇都宮. 臨床薬理 2007; 38 Suppl: S306 (ver. 1.1).

津谷喜一郎，澤田　弘．臨床試験のsponsor はスポンサーではない． 第27回日本臨床薬理学会年会. 2007.11.30, 宇都宮. 臨床薬理 2007; 38 Suppl: S268 (ver. 1.2).

粕谷晴子，津谷喜一郎，小池竜司．治験プロトコールと同意説明のための説明文書におけるファーマコジェネティクス情報の記載の現状． 第27回日本臨床薬理学会年会. 2007.11.30, 宇都宮. 臨床薬理 2007; 38 Suppl: S263 (ver. 1.1).

花房伊保里，津谷喜一郎，小池竜司．治験プロトコールでは旧版のヘルシンキ宣言が使われがちである． 第27回日本臨床薬理学会年会. 2007.11.30, 宇都宮. 臨床薬理 2007; 38 Suppl: S258 (ver. 1.1).

久代　隆，山崎亮治，熊野　璋，津谷喜一郎. 日本に代替可能薬はいくつあるか？ 第27回日本臨床薬理学会年会. 2007.11.28, 宇都宮. 臨床薬理 2007; 38 Suppl: S204 (ver. 1.1).

山崎亮治，久代　隆，熊野　璋，津谷喜一郎. エッセンシャルドラッグとジェネリックドラッグ．第27回日本臨床薬理学会年会. 2007.11.28, 宇都宮. 臨床薬理 2007; 38 Suppl: S200 (ver. 1.1).

大石裕太，成　倫慶，LOPERT Ruth, 津谷喜一郎. 自由貿易協定（FTA）における医薬品−米・韓，米・豪のケーススタディ−. 第27回日本臨床薬理学会年会. 2007.11.28, 宇都宮. 臨床薬理 2007; 38 Suppl: S198 (ver. 1.2).

辻　香織，津谷喜一郎. 日米EUにおけるドラッグラグ−ライセンサー国籍別，バイオ医薬品，治療領域別分析−. 第27回日本臨床薬理学会年会. 2007.11.28, 宇都宮. 臨床薬理 2007; 38 Suppl: S198.

宋　基央，津谷喜一郎. 1999年から2005年にかけての高血圧に対する薬剤費の変動要因分析. 第27回日本臨床薬理学会年会. 2007.11.28, 宇都宮. 臨床薬理 2007; 38 Suppl: S195 (ver. 1.2).

上嶋健治, 津谷喜一郎, 中尾一和. 循環器領域における本邦初の多施設共同無作為割付け前向き比較対照試験 JAMP studyの意義, 第27回日本臨床薬理学会年会. 2007.11.28, 宇都宮. 臨床薬理 2007; 38 Suppl: S108.

白岩 健, 福田 敬, 津谷喜一郎. ベイズ統計を用いたpravastatinの経済評価の試み. 第13回日本薬剤疫学会学術総会. 東京, 2007.11.15. 薬剤疫学 2007; 12(Suppl): S54-S55.

津谷喜一郎. 薬効評価の三「た」論法再訪 -EBMとbest case projectの時代を背景に- . 日本薬史学会2007年会, 長崎, 2007.11.11.

白岩健, 福田敬, 下妻晃二郎, 大橋靖雄, 津谷喜一郎. 大腸癌術後補助療法におけるカペシタビン (Xeloda) の薬剤経済学的分析. 日本癌治療学会第45回総会, 京都, 2007.10.25. 日本癌治療学会誌 2007; 42 (2): 860. 

五十嵐中, 福田敬, 津谷喜一郎. 禁煙治療薬バレニクリンの費用効用分析. 第66回日本公衆衛生学会総会, 松山, 2007.10.24. 日本公衆衛生雑誌 2007; 54 (10): 430.

吉田かおる, 福田敬, 亀井美和子, 他. 降圧剤、高脂血症用剤を用いた服薬アドヒアランスに関する調査. 第127回日本薬学会, 富山, 2007.3.28.

上嶋健治, 大庭幸治, 津谷喜一郎, 中尾一和. 本邦における循環器領域での大規模臨床試験の潮流. 第71回日本循環器学会総会・学術集会, 2007.3.15, 神戸, Circ J 2007; 71 Suppl I: 22-3.

Tsutani K, Yaju Y, Yoshida M, Yamaguchi N. Past, present and future of Minds: information center for clinical practiceguidelines and related areas in Japan. Asia Pacific EBM Network Conference, HongKong, 9 December 2006.

Igarashi A, Fukuda T, Tsutani K, et al. Cost-utility analysis for smoking cessation therapy in Japan. ISPOR 9th Annual European Congress, Copenhagen, Denmark, 31 October 2006. Value in Health 2006; 9 (6): A348.

Fukuda T, Mori M, Hirose N, et al. Methods of cost data collection for pharmacoeconomic study along with a clinical trial. ISPOR 2th Asia-Pacific Meeting, Shanghai, China, 6 March 2006.

Igarashi A, Takuma H, Shimamura H, et al. Cost-effectiveness analysis for smoking cessation therapy in Japan. ISPOR 2th Asia-Pacific Meeting, Shanghai, China, 6 March 2006. Abstracts. p. 180.

白岩 健, 福田 敬, 津谷喜一郎. 転移性大腸癌患者に対するbevacizumab/cetuximabの費用効果分析. 第44回日本癌治療学会総会学術総会. 東京 ,2006.10.19. 日本癌治療学会誌 2006; 41 (2): 853. (日本癌治療学会ポスター賞受賞)

白岩 健, 福田 敬, 下妻晃二郎, 大橋靖雄, 津谷喜一郎. 乳癌術後補助療法におけるtrastuzumabの薬剤経済学的分析. 第14回日本乳癌学会総会. 金沢, 2006.7.8. 日本乳癌学会総会プログラム抄録集 2006: 340.

詫間浩樹, 五十嵐中, 福田敬, 他. 禁煙支援法の経済評価に関する文献調査. 日本薬学会第126年会, 仙台, 2006.3.29. 日本薬学会第126年会講演要旨集 2006. p.190.

Takuma H, Tsutani K. Effective utilization of adverse drug reaction line lists of kampo products on the web of the ministry of health, labour and welfare of japan. The 13th international congress of oriental medicine (13th ICOM), Daegu, Republic of Korea, 11 October 2005.

Igarashi A, Takuma H, Shimamura H, et al. Developing a markov-model including tobacco-associated diseases to evaluate smoking cessation therapy in Japan. ISPOR 10th Annual International Meeting, Washington D.C, USA, 17 May 2005. Value in Health 2005; 8 (3): 312.

Tsutani K, Tamaoki M, Azuma J. ELSI in pharmacogenetics. International symposium of "Systematic Review and Meta-Analysis", Wako, Japan, 25 February 2005. Abstracts. p. 30-1.

白岩 健, 福田 敬, 津谷喜一郎. FEC50vsFEC100の薬剤経済学的分析　乳癌術後補助療FECの投与量別医療経済評価. 第43回日本癌治療学会総会学術総会. 名古屋, 2005.10.25. 日本癌治療学会誌 2005; 40 (2): 505.

成倫慶, 五十嵐中, 辻香織, 津谷喜一郎. 日韓の抗リウマチ薬適応外使用の現状. 第26回日本臨床薬理学会年会, 別府, 2005.12.2. 臨床薬理 2005; 36 (Suppl): S203.

栗山泰, 上嶋健治, 平盛勝彦, 津谷喜一郎. JAMP以降の日本での循環器領域における大規模臨床試験のレビュー. 第26回日本臨床薬理学会年会, 別府, 2005.12.3.

山積隆之介, 井上雅夫, 津谷喜一郎. 日本の年間治験参加者の推計数は約4万人. 第26回日本臨床薬理学会年会, 別府, 2005.12.3.

五十嵐中, 福田敬, 津谷喜一郎. 医薬品価格調査のものさし. 第20回国際保健医療学会総会, 東京, 2005.11.5.

五十嵐中, 津谷喜一郎. 強制実施権のリバイバル. 2005年度日本薬史学会秋季年会, 札幌, 2005.10.2. 日本薬史学雑誌 2005; 40 (2): 159.

津谷喜一郎, 五十嵐中 ,福田敬, 他. 心血管系疾患発症予防に対する低用量アスピリンの医療経済評価. 第102回日本内科学会, 大阪, 2005.4.7. 日本内科学会雑誌 2005; 94 (suppl): 160.

Igarashi A, Fukuda T, Tsutani K, Fujii S, Shinfuku N. Price difference of antipsychotic drugs in Asia. 20th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Bordeaux, France. 23 August 2004. Pharmacoepidemiology and Drug Safety 2004; 13 (Suppl. 1): 153.

Fukuda T, Igarashi A, Tsutani K. Contingent valuation method for pharmacogenetic test and drug therapy. 8th World Congress on Clinical Pharmacology and Therapeutics, Brisbane, Australia, 1 August 2004. Abstract summary. p.150.

Igarashi A, Fukuda T, Miyasaka N, Tsutani K. Economic evaluation of self-injection vs ambulatory care of anti-rheumatoid biologics (etanercept) in Japan. ISPOR 9th Annual International Meeting, Arlington, USA, 17 May 2004. Abstracts. p. 322.

Igarashi A, Tsutani K. Drug price survey along with WHO/HAI core list. Second ICIUM Conference, Chiang Mai, Thailand, 30 March 2004.

白岩 健, 福田 敬, 津谷喜一郎. 乳癌術後補助療法におけるアントラサイクリン(AC)+タキサン(T)レジメンのメタアナリシスと経済評価. 第11回日本薬剤疫学会学術総会. 福井, 2005.11.15. 薬剤疫学 2005; 10 (Suppl): S38-S39.

白岩 健, 津谷喜一郎. 日本における医薬品使用実態調査の現状. 第10回日本薬剤疫学会学術総会. 福岡, 2004.11.14. 薬剤疫学 2004; 9 (Suppl): S56-S57.

津谷喜一郎. 日本の相補代替医療のコストは3.5兆円. 第25回日本臨床薬理学会年会, 静岡, 2004.9.17.

Fukuda T, Igarashi A, Goto T, Tsutani K. Willingness to pay for hypothetical pharmacogenetic tests and drug therapies for leukemia and Alzheimer's disease. ISPOR First Asia-Pacific Conference, Kobe, 1 September 2003.

Igarashi A, Tsutani K, Fukuda T. Cost-effectiveness analysis of self injection vs anbulatory care of anti-rheumatoid biologics (etanercept) . ISPOR First Asia-Pacific Conference, Kobe, 1 September 2003. Abstracts. p.145.

津谷喜一郎, 菊田健太郎. 厚生労働省科学研究費補助事業による20の診療ガイドラインがカバーする医療費の推計. 第24回日本臨床薬理学会年会, 横浜, 2003.12.11.

五十嵐中, 津谷喜一郎. 生物学的製剤エタネルセプトの自己注射と通院治療の費用効果分析. 第18回日本臨床リウマチ学会年会, 札幌, 2003.10.3. 第18回日本臨床リウマチ学会年会講演要旨集 2003; 70.

五十嵐中, 津谷喜一郎. 海外医薬品価格の調査法. 日本薬学会第123回年会, 長崎, 2003.3.29. 日本薬学会第123回年会講演要旨集 2003; 180.

Tsutani K. Policy and politics of evidence-based medicine in Japan. International Symposium on "EBM and policy development", Tokyo, Japan, 16 Feb. 2001.

五十嵐中, 津谷喜一郎, 福田敬. 1962年キーフォーバー・ハリス修正法の議論に始まる医薬品強制実施権の歴史. 2001年度日本薬史学会秋季年会, 東京, 2001.11.10. 日本薬史学雑誌 2001; 36 (2): 190.